Anticoagulation in the trauma patient

Trauma

Volumn 7, Issue 2, 2005, Pages 63-68

  Karnik, Leena ^a   Murray, Jim ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

anticoagulationand trauma; heparin; heparin inducedthrombocytopenia; thromboprophylaxis and trauma; warfarin

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NEW DRUG; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPRESSION THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TRANSFORMATION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PATHOGENESIS; THROMBOEMBOLISM; TRAUMATOLOGY;

EID: 21244435906     PISSN: 14604086     EISSN: None     Source Type: Journal    
DOI: 10.1191/1460408605ta328oa     Document Type: Article

References (36)

1. Alving B. 2003. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101: 31-37
2. Bauer KA, Erikson BI, Lassen MR, Turpie AGG. 2001. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345: 1305-1310.
3. Bernard GR, Vincent JL, Laterre PF et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
4. British Committee for Standards in Haematology. 1998. Guidelines on oral anticoagulation. 3rd edition. Br J Haematol 101: 374-387.
5. Cartmill M, Dolan G, Byrne JL, Byrne PO. 2000. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 14: 458-461.
6. Danhof M, deBoer A, Magnani HN, Stiekame JC. 1992. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Hemostasis. 22: 73-84.
7. Dennis JW, Menawat S, Von Thron J et al. 1993. Efficacy of deep venous prophylaxis in trauma patients and identification of high-risk groups. J Trauma 35: 132-139
8. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. 2001. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345: 1298-1304.
9. Eriksson BI, Bergquist D, Kalebo P et al. 2002. Ximelagatran and Melagatran compared with dalteparin for prevention of venous thromboembolism after total hip replacement: the METHRO II randomized trial. Lancet 360: 1441-1447.
10. Eriksson BI, Agnelli G, Cohen AT et al. (METHRO III study group). 2003. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparision with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89: 288-296.
11. Geerts WH, Code KI, Jay RM et al. 1994. A prospective study of venous thromboembolism after major trauma. N Engl J Med 331: 1601-1606.
12. Geerts WH, Jay RM, Code KI et al. 1996. A comparision of low-dose heparin with low-molecular-weight heparin as prophylaxis against VTE after major trauma. N Engl J Med 335: 701-707.
13. Greinacher A, Eichler P, Lubenow N et al. 2000. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96: 846-851
14. Hirsh J, Warkentin TE, Shaughnessy SG et al. 2001. Heparin and low-molecular-weight heparin. Chest 119: 64S-94S.
15. Huhle G, Hoffmann U, Song X et al. 1999. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 106: 195-201.
16. Karni A, Holtzman R, Bass T et al. 2001. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg 67: 1098-1100.
17. Kessler C. 2002. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Intens Care Med 28(Suppl 2): S228-S234.
18. Knudson MM, Lewis FR, Clinton A et al. 1994. Prevention of venous thromboembolism in trauma patients. J Trauma 37: 480-487
19. Li J, Brown J, Levine M. 2001. Mild head injury, anticoagulants and risk of intracranial injury. Lancet 357: 771-772.
20. Meissner MH. 1998. Deep venous thrombosis in the trauma patient. Semin Vasc Surg 11: 274-282.
21. Mina AA, Bair HA, Howells GA, Bendick PJ. 2003. Complications of pre-injury warfarin use in the trauma patient. J Trauma 54: 842-847.
22. Park P, Fewel ME, Thompson BG, Hoff JT. 2003. Recombinant activated factor VII for rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 53: 34-38.
23. Preston FE, Laidlaw ST, Sampson B, Kitchen S. 2002. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 116: 619-624.
24. Rogers FB, Cipolle MD, Velmahos G et al. 2002. Practice Management Guidelines for the prevention of venous thromboembolism in trauma patients: The EAST Practice management guidelines Work Group. J Trauma 53: 142-164.
25. Schwarcz TH, Quick RC, Minion DJ et al. 2001. Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. J Vasc Surg 34: 447-452.
26. Shackford SR, Davis JW, Hollingsworth-Fridlund P et al. 1990. Venous thromboembolism in patients with major trauma. Am J Surg 159: 365-369.
27. Sharpe RP, Gupta R, Gracias VH et al. 2002. Incidence and natural history of below-knee deep venous thrombosis in high-risk trauma patients. J Trauma 53: 1048-1052.
28. Spain DA, Bergamini JM, Hoffmann JF et al. 1998. Comparison of sequential compression devices and foot pumps for prophylaxis of deep venous thrombosis in high-risk trauma patients. Am Surg 64: 522-526.
29. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. 2002a. Post operative Fondaparinux versus post operative Enoxaparin for the prevention of venous thromboembolism after elective hip replacement surgery: a randomized double blind trial. Lancet 359: 1721-1726.
30. Turpie AG, Eriksson BI, Lassen MR et al. 2002b. A meta-analysis of fondaparinux versus enoxaparin in prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 11: 182-188.
31. Upchurch GR Jr, Demling RH, Davies J et al. 1995. Efficacy of subcutaneous heparin in prevention of venous thromboembolic events in trauma patients. Am Surg 61: 749-755.
32. Velmahos GC, Kern J, Chan LS et al. 2000. Prevention of venous thrombo-embolism after trauma: an evidence-based report - part II: analysis of risk factors and evaluation of the role of vena cava filters. J Trauma 49: 140-144.
33. Veshchev I, Elran H, Salame K. 2002. Recombinant coagulation factor VIIa for rapid preoperative correstionof warfarin-relatedcoagulopathyinpatients with acute subdural hematoma. Med Sci Monit 8: CS98-CS100.
34. Warkentin TE, Kelton JG. 2001. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344: 1286-1292.
35. Wheeler HB, Anderson FA Jr. 1993. Use of non-invasive tests as the basis for treatment of deep vein thrombosis. In: Bernstein EF ed. Vascular diagnosis, 4th ed. St Louis: Mosby; 1894-1912.
36. Wheeler HB, Anderson FA Jr. 1995. Diagnostic methods for deep vein thrombosis. Haemostasis 25: 6-26.